this article is about a big company named Johnson & Johnson. They did better than people thought in making money during the second part of this year. They made 22.45 billion dollars from selling things. The person in charge said they have lots of good things coming up to sell, so they think they will keep doing good. Some people who look at how well companies are doing changed how much they think Johnson & Johnson will make in the future. Some people think they will make less money because of some stuff they bought, but other people still think they can make a lot of money. Their shares, which are like pieces of the company that people can buy, went up a little in price. Read from source...

The article `These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results` by Avi Kapoor discusses Johnson & Johnson's Q2 results. However, the article also points out that some of the analysts covering Johnson & Johnson have changed their forecasts after the Q2 results were released. Morgan Stanley analyst Terence Flynn maintained the company with an Equal-Weight rating, but increased the price target from $167 to $169. On the other hand, TD Cowen analyst Joshua Jennings maintained a Buy rating but cut the price target from $195 to $185. RBC Capital analyst Shagun Singh reiterated an Outperform rating while maintaining a price target of $175. While some of the changes were downward revisions, others remained the same, showing mixed opinions among the analysts. Despite this, the company's Q2 results were better than expected.

1. Johnson & Johnson (JNJ) reported better-than-expected Q2 earnings. Adjusted EPS of $2.82, up 10.2% YoY, beat consensus of $2.70. Sales of $22.45 billion, up 4.3% YoY, beat consensus of $22.31 billion.

2. Morgan Stanley analyst Terence Flynn maintained Johnson & Johnson with an Equal-Weight rating and boosted the price target from $167 to $169.

3. TD Cowen analyst Joshua Jennings maintained the stock with a Buy rating, while cutting the price target from $195 to $185.

4. RBC Capital analyst Shagun Singh reiterated Johnson & Johnson with an Outperform rating and maintained a price target of $175.

Risks:

- The pharma giant revised its fiscal year 2024 adjusted EPS guidance to $9.97–$10.07, down from prior guidance of $10.57–$10.72, to reflect the impact of recent acquisitions.

- The company's Q2 results were aided by recent acquisitions of Shockwave Medical, Proteologix, and NM26 Bispecific Antibody.

- Despite positive Q2 results, some analysts have revised their price targets downwards, suggesting potential volatility in the stock's future performance.